Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UCLM 802

X
Drug Profile

UCLM 802

Alternative Names: Anti-Mesothelin CAR-T cell therapy - UTC Therapeutics; CD40 ligand expressing MSLN-CAR T cell therapy - UTC Therapeutics; CD40 ligand targeting anti-mesothelin chimeric antigen receptor T cell therapy - UTC Therapeutics; UCLM-802

Latest Information Update: 11 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UTC Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 27 Apr 2023 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease) in China (IV) (NCT05848999)
  • 24 Mar 2023 UTC Therapeutics plans a phase I trial for Solid tumours (Late staged, Relapsed or Refractory, Second-line therapy or greater) (NCT05783089)
  • 20 Mar 2023 UTC Therapeutics plans a phase I trial for Solid tumours (Late stage disease, In adults, In elderly, Second line therapy or greater) (IV) (NCT05775666)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top